Chordoma Clinical Trial
Official title:
Phase I Safety Study of Stereotactic Radiosurgery With Concurrent and Adjuvant PD-1 Antibody Nivolumab in Subjects With Recurrent or Advanced Chordoma
This phase I trial studies the side effects of nivolumab with or without stereotactic radiosurgery (SRS) in treating patients with chordoma that has come back or spread from where it started to other places in the body. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. It is not yet known whether giving nivolumab with or without stereotactic radiosurgery may work better in treating patients with chordoma.
PRIMARY OBJECTIVES: I. To assess the safety profile of nivolumab alone and nivolumab in combination with stereotactic radiosurgery to treat patients with recurrent or advanced chordoma. SECONDARY OBJECTIVES: I. To evaluate toxicity and tolerability of nivolumab alone and nivolumab in combination with stereotactic radiosurgery. II. To estimate growth modulation index on target lesion. III. To estimate a clinical response (partial response [PR] + complete response [CR] within 6 month + stable disease [SD] beyond 6 months). IV. To assess progression-free survival and progression-free survival (PFS) rate at 6 months. V. To assess overall survival rate at 1 year, 3 years and 5 years. TERTIARY OBJECTIVES: I. To explore peripheral blood immune response during and after treatment. OUTLINE: Patients are assigned to 1 of 2 arms. ARM I: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1. Courses repeat every 14 days for 2 years in the absence of disease progression or unacceptable toxicity. ARM II: Patients receive nivolumab as in Arm I. Patients undergo stereotactic radiosurgery (SRS) as per standard of care on day 8 of course 1. After completion of study treatment, patients are followed up at 100 days and every 10 weeks thereafter. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03955042 -
Pemetrexed for the Treatment of Chordoma
|
Phase 1 | |
Completed |
NCT01347307 -
Stereotactic Body Radiotherapy for Spine Tumors
|
N/A | |
Active, not recruiting |
NCT00496119 -
Proton Beam Therapy for Chordoma Patients
|
Phase 2 | |
Recruiting |
NCT06029218 -
Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy
|
N/A | |
Completed |
NCT03595228 -
BN Brachyury and Radiation in Chordoma
|
Phase 2 | |
Recruiting |
NCT06140732 -
Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma
|
Phase 2 | |
Active, not recruiting |
NCT01175109 -
Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
|
Phase 1 | |
Completed |
NCT00150072 -
Efficacy and Safety of Imatinib in Chordoma
|
Phase 2 | |
Terminated |
NCT00003926 -
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05041127 -
Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma
|
Phase 2 | |
Recruiting |
NCT05861245 -
Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base
|
N/A | |
Completed |
NCT00464620 -
Trial of Dasatinib in Advanced Sarcomas
|
Phase 2 | |
Completed |
NCT02383498 -
QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma
|
Phase 2 | |
Recruiting |
NCT03242382 -
Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.
|
Phase 2 | |
Completed |
NCT02520128 -
A Study of IMRT in Primary Bone and Soft Tissue Sarcoma
|
N/A | |
Recruiting |
NCT01567046 -
Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas
|
N/A | |
Recruiting |
NCT02986516 -
Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease
|
N/A | |
Completed |
NCT00919269 -
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
|
||
Active, not recruiting |
NCT03083678 -
Afatinib in Locally Advanced and Metastatic Chordoma
|
Phase 2 | |
Completed |
NCT00713037 -
Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With Chordomas
|
N/A |